Dosage forms for oral administration of zoledronic acid or related compounds for treating disease

1. A method of delivering zoledronic acid to the blood of a human being comprising orally administering zoledronic acid in the disodium salt form to a human being in need of treatment with zoledronic acid, wherein the human being is instructed not to eat or drink for at least 1 hour before and at least 30 minutes after the zoledronic acid in the disodium salt form is administered, wherein the zoledronic acid in the disodium salt form is administered in a manner that results in a bioavailability of zoledronic acid in the human being of 1% to about 4%.

2. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a manner that results in a bioavailability of zoledronic acid in the human being of 1.5% to 3%.

3. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a dosage form that contains at least 10% w/w of zoledronic acid in the disodium salt form.

4. The method of claim 1 , wherein about 10 mg to about 200 mg of zoledronic acid in the disodium salt form is administered within a month.

5. The method of claim 1 , wherein about 25 mg to about 150 mg of zoledronic acid in the disodium salt form is administered within a month.

6. The method of claim 1 , wherein about 400 mg to about 500 mg of zoledronic acid in the disodium salt form is administered within a month.

7. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered only once.

8. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered once daily to once weekly.

9. The method of claim 1 , wherein there is a period of about one week to about one month between instances of administration of the zoledronic acid in the disodium salt form.

10. The method of claim 1 , wherein there is a period of at least one month between instances of administration of the zoledronic acid in the disodium salt form.

11. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered once a month for only 3 months.

12. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a manner that results in a bioavailability of zoledronic acid in the human being of 1.2% to 3%.

13. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a manner that results in a bioavailability of zoledronic acid in the human being of 1.5% to 2%.

14. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a manner that results in a bioavailability of zoledronic acid in the human being of 2% to 3%.

15. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a solid dosage form.

16. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a solid dosage form that has a hardness of at least about 5 kPa.

17. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a solid dosage form that contains about 50% w/w to about 90% w/w of zoledronic acid in the disodium salt form.

18. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a manner that results in the zoledronic acid having a 24 hour sustained plasma factor of at least about 3.

19. The method of claim 1 , wherein the human being remains upright for at least one hour after administration of the zoledronic acid in the disodium salt form.

20. The method of claim 12 , wherein about 30 mg to about 500 mg of zoledronic acid in the disodium salt form is administered per month.

21. A method of delivering zoledronic acid to the blood of a human being comprising orally administering zoledronic acid in the disodium salt form to a human being in need of treatment with zoledronic acid, wherein the human being is instructed not to eat or drink for at least 1 hour before and at least 30 minutes after the zoledronic acid in the disodium salt form is administered, wherein the zoledronic acid in the disodium salt form is administered in an amount and frequency that results in an AUC of zoledronic acid that is about 100 ng·h/mL to about 2000 ng·h/mL each time the zoledronic acid in the disodium salt form is administered.

22. The method of claim 21 , wherein about 10 mg to about 100 mg of zoledronic acid in the disodium salt form is administered within one month.

23. The method of claim 21 , wherein about 100 mg to about 300 mg of zoledronic acid in the disodium salt form is administered within one month.

24. The method of claim 21 , wherein about 200 mg to about 300 mg of zoledronic acid in the disodium salt form is administered within one week.

25. The method of claim 21 , wherein there is a period of about one week to about one month between instances of administration of zoledronic acid in the disodium salt form.

26. The method of claim 21 , wherein the zoledronic acid in the disodium salt form is administered at least three times.

27. A method of delivering zoledronic acid to the blood of a human being comprising orally administering zoledronic acid in the disodium salt form to a human being in need of treatment with zoledronic acid; wherein the zoledronic acid in the disodium salt form is administered at least once weekly and no more often than once daily and in a manner that results in a bioavailability of zoledronic acid in the human being of 1% to about 4% after each administration.

28. The method of claim 27 , wherein about 30 mg to about 200 mg of zoledronic acid in the disodium salt form is administered within two months.

29. The method of claim 27 , wherein about 300 mg to about 500 mg of zoledronic acid in the disodium salt form is administered within two months.

30. The method of claim 27 , wherein about 100 mg to about 500 mg of zoledronic acid in the disodium salt form is administered within two months.